Role of the mucins in pathogenesis of COPD: implications for therapy.

Lo Bello, F; Ieni, A; Hansbro, PM; Ruggeri, P; Di Stefano, A; Nucera, F; Coppolino, I; Monaco, F; Tuccari, G; Adcock, IM; Caramori, G

Role of the mucins in pathogenesis of COPD: implications for therapy.

Lo Bello, F

Ieni, A

Hansbro, PM

Ruggeri, P

Di Stefano, A

Nucera, F

Coppolino, I

Monaco, F

Tuccari, G

Adcock, IM

Caramori, G

Permalink

Publication Type:: Journal Article
Citation:: Expert Rev Respir Med, 2020, pp. 1 - 19
Issue Date:: 2020-03-19

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (1.17 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Lo Bello, F https://orcid.org/0000-0002-7825-9368	en_US
dc.contributor.author	Ieni, A https://orcid.org/0000-0003-2878-3572	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Ruggeri, P https://orcid.org/0000-0003-0379-9869	en_US
dc.contributor.author	Di Stefano, A https://orcid.org/0000-0003-3479-0875	en_US
dc.contributor.author	Nucera, F https://orcid.org/0000-0001-8454-5363	en_US
dc.contributor.author	Coppolino, I https://orcid.org/0000-0003-1707-8958	en_US
dc.contributor.author	Monaco, F https://orcid.org/0000-0002-5617-7943	en_US
dc.contributor.author	Tuccari, G https://orcid.org/0000-0002-1561-4246	en_US
dc.contributor.author	Adcock, IM https://orcid.org/0000-0003-2101-8843	en_US
dc.contributor.author	Caramori, G https://orcid.org/0000-0002-9807-327X	en_US
dc.date.available	2021-03-22T18:04:31Z
dc.date.issued	2020-03-19	en_US
dc.identifier.citation	Expert Rev Respir Med, 2020, pp. 1 - 19	en_US
dc.identifier.uri	http://hdl.handle.net/10453/139160
dc.description.abstract	Introduction: Evidence accumulated in the last decade has started to reveal the enormous complexity in the expression, interactions and functions of the large number of different mucins present in the different compartments of the human lower airways. This occurs both in normal subjects and in COPD patients in different clinical phases and stages of severity.Areas covered: We review the known physiological mechanisms that regulate mucin production in human lower airways of normal subjects, the changes in mucin synthesis/secretion in COPD patients and the clinical efficacy of drugs that modulate mucin synthesis/secretion.Expert opinion: It is evident that the old simplistic concept that mucus hypersecretion in COPD patients is associated with negative clinical outcomes is not valid and that the therapeutic potential of 'mucolytic drugs' is under-appreciated due to the complexity of the associated molecular network(s). Likewise, our current knowledge of the effects of the drugs already available on the market that target mucin synthesis/secretion/structure in the lower airways is extremely limited and often indirect and more well-controlled clinical trials are needed in this area.	en_US
dc.language	eng	en_US
dc.relation	http://purl.org/au-research/grants/nhmrc/APP1179092
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1179092
dc.relation	http://purl.org/au-research/grants/nhmrc/1175134
dc.relation.ispartof	Expert Rev Respir Med	en_US
dc.relation.isbasedon	10.1080/17476348.2020.1739525	en_US
dc.rights	This is an Accepted Manuscript of an article Published by Taylor & Francis in Expert review of respiratory medicine On 19 Mar 2020 available online: https://www.tandfonline.com/doi/full/10.1080/17476348.2020.1739525
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.subject.classification	Respiratory System	en_US
dc.title	Role of the mucins in pathogenesis of COPD: implications for therapy.	en_US
dc.type	Journal Article
utslib.location.activity	England	en_US
utslib.for	1117 Public Health and Health Services	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
pubs.publication-status	Published online	en_US

Abstract:

Introduction: Evidence accumulated in the last decade has started to reveal the enormous complexity in the expression, interactions and functions of the large number of different mucins present in the different compartments of the human lower airways. This occurs both in normal subjects and in COPD patients in different clinical phases and stages of severity.Areas covered: We review the known physiological mechanisms that regulate mucin production in human lower airways of normal subjects, the changes in mucin synthesis/secretion in COPD patients and the clinical efficacy of drugs that modulate mucin synthesis/secretion.Expert opinion: It is evident that the old simplistic concept that mucus hypersecretion in COPD patients is associated with negative clinical outcomes is not valid and that the therapeutic potential of 'mucolytic drugs' is under-appreciated due to the complexity of the associated molecular network(s). Likewise, our current knowledge of the effects of the drugs already available on the market that target mucin synthesis/secretion/structure in the lower airways is extremely limited and often indirect and more well-controlled clinical trials are needed in this area.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/139160